Kuros Biosciences Management
Management criteria checks 2/4
Kuros Biosciences' CEO is Chris Fair, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is CHF1.34M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth CHF3.09M. The average tenure of the management team and the board of directors is 1.1 years and 6.2 years respectively.
Key information
Chris Fair
Chief executive officer
CHF 1.3m
Total compensation
| CEO salary percentage | 24.6% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.1yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Recent updates
Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up
Oct 24Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CHF 9m |
| Mar 31 2024 | n/a | n/a | -CHF 11m |
| Dec 31 2023 | CHF 1m | CHF 329k | -CHF 14m |
| Sep 30 2023 | n/a | n/a | -CHF 15m |
| Jun 30 2023 | n/a | n/a | -CHF 16m |
| Mar 31 2023 | n/a | n/a | -CHF 15m |
| Dec 31 2022 | CHF 36k | n/a | -CHF 15m |
| Sep 30 2022 | n/a | n/a | -CHF 13m |
| Jun 30 2022 | n/a | n/a | -CHF 11m |
| Mar 31 2022 | n/a | n/a | -CHF 9m |
| Dec 31 2021 | CHF 36k | n/a | -CHF 8m |
Compensation vs Market: Chris's total compensation ($USD1.51M) is about average for companies of similar size in the Swiss market ($USD1.35M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Fair (54 yo)
1.1yrs
Tenure
CHF 1,337,700
Compensation
Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operating Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | CHF 1.34m | 0.35% CHF 3.1m | |
| Chief Financial Officer | 1.5yrs | no data | no data | |
| COO & GM of BV | 1.1yrs | no data | no data | |
| President of Innovation and Strategy & Executive Director | 1.1yrs | CHF 873.70k | no data | |
| Senior Vice President of Marketing & Business Development | less than a year | no data | no data | |
| Vice President of Global Human Resources | less than a year | no data | no data | |
| Chief Development Officer | 8.3yrs | no data | no data | |
| Chief Commercial Officer | 6.6yrs | no data | no data | |
| Senior Vice President of Medical & Clinical Affairs | less than a year | no data | no data | |
| Consultant | 6.5yrs | no data | no data |
1.1yrs
Average Tenure
56yo
Average Age
Experienced Management: KURN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | CHF 1.34m | 0.35% CHF 3.1m | |
| President of Innovation and Strategy & Executive Director | 6.4yrs | CHF 873.70k | no data | |
| Chairman | 7.4yrs | CHF 92.60k | 1.94% CHF 16.9m | |
| Independent Non-Executive Director | 6.4yrs | CHF 73.80k | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Strategic Advisory Board | 6.2yrs | no data | no data | |
| Member of Strategic Advisory Board | 6.2yrs | no data | no data | |
| Member of Strategic Advisory Board | 6.2yrs | no data | no data | |
| Member of Strategic Advisory Board | 6.2yrs | no data | no data |
6.2yrs
Average Tenure
56.5yo
Average Age
Experienced Board: KURN's board of directors are considered experienced (6.2 years average tenure).